Francesco De Rubertis

This profile gathers the share dealings of Francesco De Rubertis across 2 companies, led by Centessa Pharmaceuticals plc and Minerva Neurosciences, Inc. The record holds 24 filings, for trades running from 10 August 2016 to 24 June 2026.

In open-market terms, that means 12 purchases worth €12.0M on one side and 1 sale worth €8.9M on the other. On balance, insiders were net buyers of €3.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant.

A typical purchase (the median) is worth €172k. 12 out of 12 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 24 June 2026: a transaction, in Centessa Pharmaceuticals plc. The last insider purchase was made public on 6 December 2021, 1,782 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.